135 related articles for article (PubMed ID: 37145121)
41. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
42. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
43. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
[TBL] [Abstract][Full Text] [Related]
44. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Warren A; Langley JM; Thomas W; Scott J
Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
[TBL] [Abstract][Full Text] [Related]
45. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
46. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
47. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
48. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
Ohler KH; Pham JT
Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
[TBL] [Abstract][Full Text] [Related]
50. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC
Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
[TBL] [Abstract][Full Text] [Related]
51. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
52. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
[TBL] [Abstract][Full Text] [Related]
53. Pediatric intensive care unit admission due to respiratory syncytial virus: Retrospective multicenter study.
Kang JM; Lee J; Kim YK; Cho HK; Park SE; Kim KH; Kim MJ; Kim S; Kim YJ
Pediatr Int; 2019 Jul; 61(7):688-696. PubMed ID: 31107995
[TBL] [Abstract][Full Text] [Related]
54. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
55. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
[TBL] [Abstract][Full Text] [Related]
56. Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014).
Borecka R; Lauterbach R
Dev Period Med; 2018; 22(4):308-314. PubMed ID: 30636227
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
[TBL] [Abstract][Full Text] [Related]
58. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
59. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
[TBL] [Abstract][Full Text] [Related]
60. Administration of Palivizumab in the NICU.
Vendetti N; Gerber JS; Sammons JS; Fisher BT; Zaoutis TE; Coffin SE
Hosp Pediatr; 2016 Jun; 6(6):354-8. PubMed ID: 27164941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]